MedTrace Logo

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

NCT03151876 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2018-07-18

No results posted yet for this study

Summary

The goal of this clinical research study is to evaluate effectiveness and safety of ChiCGB regimen( chidamide, cladribine, gemcitabine and busulfan).

Busulfan are designed to kill cancer cells by binding to DNA (the genetic material of cells), which may cause cancer cells to die.

Gemcitabine and cladribine are designed to disrupt the growth of cancer cells, which may cause cancer cells to die. It may help to increase the effect of busulfan on cancer cells by not allowing these cells to repair the DNA damage caused by busulfan.

Chidamide is designed to open up the DNA and allow greater access to drugs that bind to DNA, such as cladribine, gemcitabine, busulfan.

Conditions

Interventions

DRUG

Chidamide

30 mg oral twice weekly for 2 weeks

DRUG

Cladribine

6 mg/m2 intravenously daily for 5 days

DRUG

gemcitabine

2500 mg/m2 intravenously twice weekly for 1 week

DRUG

Busulfan

3.2 mg/kg intravenously daily for 4 days

PROCEDURE

Autologous hematopoietic stem cell transplantation

autologous hematopoietic stem cells infusion after ChiCGB chemotherapy

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Ting Liu, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-12
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03151876 on ClinicalTrials.gov